SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-236658
Filing Date
2022-09-01
Accepted
2022-09-01 17:30:03
Documents
16
Period of Report
2022-09-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d283919d8k.htm   iXBRL 8-K 30969
2 EX-10.1 d283919dex101.htm EX-10.1 24712
3 EX-99.1 d283919dex991.htm EX-99.1 11957
7 GRAPHIC g283919g0902012822410.jpg GRAPHIC 3147
8 GRAPHIC g283919new.jpg GRAPHIC 19210
  Complete submission text file 0001193125-22-236658.txt   238702

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ikt-20220901.xsd EX-101.SCH 2862
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20220901_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20220901_pre.xml EX-101.PRE 11712
10 EXTRACTED XBRL INSTANCE DOCUMENT d283919d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 221222447
SIC: 2836 Biological Products, (No Diagnostic Substances)